FAKTOR-OPTIONSSCHEIN - LIGAND PHARMACEUTICALS Share Price

Certificat

DE000MG23CA5

Real-time Bid/Ask 11:54:53 04/06/2024 BST
11.47 EUR / 12.05 EUR -0.76% Intraday chart for FAKTOR-OPTIONSSCHEIN - LIGAND PHARMACEUTICALS
Current month+9.32%
1 month+56.75%
Date Price Change
04/06/24 11.47 -3.21%
03/06/24 11.85 +9.32%
31/05/24 10.84 +4.03%
30/05/24 10.42 -3.70%
29/05/24 10.82 -2.26%

Delayed Quote Börse Stuttgart

Last update June 04, 2024 at 11:11 am

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying LIGAND PHARMACEUTICALS INCORPORATED
Issuer Morgan Stanley
WKN MG23CA
ISINDE000MG23CA5
Date issued 10/04/2024
Strike 58.62 $
Maturity Unlimited
Parity 2.27 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.12
Lowest since issue 6.12
Spread 0.58
Spread %4.81%

Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Sector
-
More about the company

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Ligand Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
87.91 USD
Average target price
116.8 USD
Spread / Average Target
+32.86%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW